Overview

Price chart · mood · technical indicators

BIAF

bioAffinity Technologies, Inc.stock Healthcare

Diagnostics & Research

$2.1865.54%Current Market Mood:Bearish

Market Mood

Price Range (1Y)

$0.69$15.00

Current: $2.18

Market Comparison

vs Healthcare Sector & Diagnostics & Research Industry

BIAF

-65.54%

1Y Performance

Healthcare

Sector 1Y

Diagnostics & Research

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-8.660.0% YoY

Profit margin-242.0%HEALTHCARE

Market cap$9.9MMicro cap

Valuation

Forward P/E: —
PEG ratio: —
P/B: 1.36
P/S (TTM): 1.60
EV/EBITDA: -0.21

Profitability & growth

ROE (TTM): -301.8%
Operating margin: -197.0%
Revenue growth YoY: -27.8%
Dividend yield: —
Beta: -0.81

Last earnings

Mar 13, 2026 · Reported $-0.70

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About bioAffinity Technologies, Inc.

Company profile

bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.

Classification

Sector: Healthcare
Industry: Diagnostics & Research
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 3300 NACOGDOCHES ROAD, SAN ANTONIO, TX
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$9.9M

Shares outstanding$4.5M

52W high$15.00

52W low$0.69

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

BIAF

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

bioAffinity Technologies (BIAF) wins approval for major equity plan, offerings and reverse split

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment

Military medical center joins 40-patient asthma, COPD study

BioAffinity stock surges 113.8% in 3 months: What's driving the rally?

BioAffinity stock surges 113.8% in 3 months: What's driving the rally?

New Case Study Shows bioAffinity Technologies CyPath Lung Diagnostic Helps Avoid Unnecessary Lung Biopsy

CyPath® Lung Diagnostic Helps Defer Unnecessary Biopsy

CyPath Lung case study at bioAffinity (NASDAQ: BIAF) shows biopsy deferred

A 30-mm lung nodule looked cancerous; another scan showed it was not

New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

BIAF PE Ratio & Valuation, Is BIAF Overvalued

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16

bioAffinity Showcases CyPath Lung Test at Cleveland Clinic

CyPath Lung spotlight for bioAffinity Technologies (Nasdaq: BIAF)

BIAFW Stock News Today | Earnings, Events & Price Alerts

BIAF stock gains as CyPath sales surge 146% in Q1

BIAF Stock Price $3.76 | bioAffinity Technologies, Inc. Live Quote

bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

About bioAffinity Technologies, Inc.

Classification

Company profile

BIAF

Market Comparison

BIAF Market Analysis

Overview

BIAF

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

bioAffinity Technologies (BIAF) wins approval for major equity plan, offerings and reverse split

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment

Military medical center joins 40-patient asthma, COPD study

BioAffinity stock surges 113.8% in 3 months: What's driving the rally?

BioAffinity stock surges 113.8% in 3 months: What's driving the rally?

New Case Study Shows bioAffinity Technologies CyPath Lung Diagnostic Helps Avoid Unnecessary Lung Biopsy

CyPath® Lung Diagnostic Helps Defer Unnecessary Biopsy

CyPath Lung case study at bioAffinity (NASDAQ: BIAF) shows biopsy deferred

A 30-mm lung nodule looked cancerous; another scan showed it was not

New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

BIAF PE Ratio & Valuation, Is BIAF Overvalued

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16

bioAffinity Showcases CyPath Lung Test at Cleveland Clinic

CyPath Lung spotlight for bioAffinity Technologies (Nasdaq: BIAF)

BIAFW Stock News Today | Earnings, Events & Price Alerts

BIAF stock gains as CyPath sales surge 146% in Q1

BIAF Stock Price $3.76 | bioAffinity Technologies, Inc. Live Quote

bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

About bioAffinity Technologies, Inc.

Classification

Company profile

BIAF

Market Comparison